Skip to content
A Phase 3 placebo-controlled clinical trial which assessed the efficacy of lorcaserin, a novel selective agonist of the serotonin 2C receptor, in reducing the weight in obese patients.
Analysis showed that 47% of lorcaserin patients lost at least 5% of their body weight, compared to 25% of placebo patients. Lorcaserin patients lost an average of 6%/6 kg, compared to 3%/3 kg for those taking a placebo.
Abbreviation Behavioral modification and LOrcaserin Second Study for Obesity Management
References J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77.